Common jobs held by immigrant women may put them at increased risk of breast cancerCommon jobs held by immigrant women may put them at increased risk of breast cancer
Many immigrant women in the U.S. work in jobs that may expose them to chemicals linked to breast cancer, according to a new study led by Silent Spring Institute. The study is among the first to examine how job-related chemical exposures may contribute to breast cancer risk among foreign-born workers, especially in jobs with fewer health and safety protections.
Real-World Data Back GLP-1s in Asthma, Cardiopulmonary ConditionsReal-World Data Back GLP-1s in Asthma, Cardiopulmonary Conditions
(MedPage Today) — CHICAGO — A series of large, real-world analyses supported benefit of GLP-1 receptor agonists in cardiopulmonary indications for patients with type 2 diabetes, researchers reported at the CHEST annual meeting hosted by the… (MedPage Today) — CHICAGO — A series of large, real-world analyses supported benefit of GLP-1 receptor agonists in cardiopulmonary Read More
Bariatric surgery in a pill bottleBariatric surgery in a pill bottle
More than 37 million Americans have type 2 diabetes, a chronic disorder affecting the body’s ability to regulate and use sugar. According to the CDC, it’s the country’s seventh leading cause of death. Type 2 diabetes can be treated with lifestyle changes and medications, including insulin, a sugar-regulating hormone.
5 Mistakes I Made When I Started A GLP-15 Mistakes I Made When I Started A GLP-1
Weight loss medications can be lifesaving for people who need them — but there are errors you’ll want to avoid. Weight loss medications can be lifesaving for people who need them — but there are errors you’ll want to avoid.
Opinion: Trump’s $150-per-month GLP-1 plan won’t reach people like meOpinion: Trump’s $150-per-month GLP-1 plan won’t reach people like me
On Oct. 16, President Trump promised to slash the price of brand-name GLP-1 drugs like Ozempic and Wegovy to $150 a month. Even after a top health official suggested price negotiations between drugmakers and the administration were ongoing, the announcement sent Novo Nordisk and Eli Lilly stocks tumbling. For patients who’ve been priced out, that Read More
Doctors using AI mammogram readings to predict breast cancer riskDoctors using AI mammogram readings to predict breast cancer risk
Breast cancer is the second-leading cause of cancer deaths in women. About one in eight women will be diagnosed with the disease in their lifetimes. To combat that, some doctors are using AI as a tool to help them not only detect breast cancer, but also predict a woman’s risk factors. Dr. Connie Lehman, founder of Clarity, joins CBS News to discuss the first FDA-authorized AI platform used to predict a woman’s 5-year risk of developing breast cancer.
New drug study shows improved survival for early breast cancerNew drug study shows improved survival for early breast cancer
Mayo Clinic researchers collaborated on a new study led by Eli Lilly showing that the drug abemaciclib improves survival for people with high-risk, early-stage breast cancer.
An understudied type of breast cancer poses a lurking threatAn understudied type of breast cancer poses a lurking threat
University of Colorado Cancer Center member Matthew Sikora, Ph.D., is a national leader in research into an understudied subtype of breast cancer that’s on the rise in American women, is often more difficult to detect than other forms of breast cancer, and has sharply lower survival rates several years after diagnosis than the most common type of breast cancer.
A Potential Aid to Identify Women With Breast Cancer Treatment-Related Heart RisksA Potential Aid to Identify Women With Breast Cancer Treatment-Related Heart Risks
(MedPage Today) — A risk model based on readily available clinical and demographic information accurately identified women at risk of heart failure (HF) or cardiomyopathy (CM) after breast cancer treatment, a large cohort study showed.
Application…
Beauty Mogul Laura Geller Opens Up on Breast Cancer JourneyBeauty Mogul Laura Geller Opens Up on Breast Cancer Journey
Makeup mogul Laura Geller sits down with TODAY’s Jill Martin to share her journey of building her namesake brand, surviving breast cancer, and why her beauty line dedicates its marketing and message to women over 40.